1. Home
  2. BBWI vs ADPT Comparison

BBWI vs ADPT Comparison

Compare BBWI & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bath & Body Works Inc.

BBWI

Bath & Body Works Inc.

N/A

Current Price

$21.40

Market Cap

3.8B

ML Signal

N/A

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

N/A

Current Price

$29.22

Market Cap

4.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BBWI
ADPT
Founded
1963
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
4.5B
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
BBWI
ADPT
Price
$21.40
$29.22
Analyst Decision
Hold
Strong Buy
Analyst Count
18
8
Target Price
$24.93
★ $32.57
AVG Volume (30 Days)
★ 6.0M
2.0M
Earning Date
11-19-2026
11-04-2026
Dividend Yield
★ 3.79%
N/A
EPS Growth
N/A
★ 63.89
EPS
★ 1.49
N/A
Revenue
★ $7,291,000,000.00
$276,976,000.00
Revenue This Year
N/A
$10.85
Revenue Next Year
$1.69
$21.60
P/E Ratio
$14.18
★ N/A
Revenue Growth
N/A
★ 54.77
52 Week Low
$14.28
$12.00
52 Week High
$24.94
$32.21

Technical Indicators

Market Signals
Indicator
BBWI
ADPT
Relative Strength Index (RSI) 53.15 58.55
Support Level $17.60 $24.02
Resistance Level $23.86 $29.92
Average True Range (ATR) 0.82 1.83
MACD -0.25 0.35
Stochastic Oscillator 11.69 60.05

Price Performance

Historical Comparison
BBWI
ADPT

About BBWI Bath & Body Works Inc.

Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with just 4% of sales from international markets in fiscal 2025. For fiscal 2025, 77% of sales stemmed from the brick-and-mortar network of more than 1,900 retail stores, similar to 2024 levels, as consumer shopping patterns remained normal. Future growth is expected from store upgrades, digital and international channels, as well as adjacent category expansions like lip.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: